OCT 10, 2019 12:00 PM PDT

Tumor Mutation Burden: Challenges and opportunities of measuring and interpreting tumor mutational burden for patient care

Sponsored by: QIAGEN
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Associate Professor, Pathology; Associate Director, Residency Program; Medical Director, Cytogenetics Laboratory AUMC.
    Biography
      Currently, Dr.Ravindra Kolhe is an Associate Professor in the Department of Pathology at the Augusta University in Augusta, Georgia, and divides his time between directing Molecular Pathology, Cytogenetics, Breast Pathology, teaching, and research. He is the CLIA laboratory director for the Georgia Esoteric & Molecular Labs and also serves as the Medical Director for the Cytogenetics Laboratory. As a Molecular and Genetic Pathologist, he is actively engaged in molecular and cytogenetic evaluation of patient samples as a part of the multi- disciplinary clinical team treating patients in a personalized and precision medicine model. As a Breast Pathologist, he provides expert opinions for the breast multidisciplinary tumor boards, consultation and second opinion to difficult breast cancer patients referred to Georgia Cancer Center. Dr. Kolhe is an physician-scientist with expertise in basic mechanisms of tumor immunology, including tolerogenic DCs, Tregs, and the indoleamine 2,3-dioxygenase pathway He has over 160 publications, including peer-reviewed articles, abstracts and invited reviews most in the realm of the molecular pathology of various malignancies.

    Abstract

    Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation load increases the likelihood that immunogenic neoantigens expressed by tumor cells may induce a response to immunotherapy.  However, TMB estimation and reporting can be heavily influenced by differing working processes across clinical and research laboratories; primarily, the choice of assay, platform, and how the assay is implemented and interpreted. To streamline and standardize this process at scale, QIAGEN offers an end to end solution, from detection to interpretation of TMB and other somatic alterations.

    In this webinar, we will provide insights into the implementation of the QIAseq Tumor Mutational Burden (TMB) Panel in the molecular diagnostics lab. This comprehensive cancer panel is capable of interrogating TMB, microsatellite instability (MSI), and other actionable alterations in a single assay, using specialized chemistry to remove false positives. Subsequently, we will discuss how QIAGEN Clinical Insight Interpret can streamline insights from comprehensive cancer profiles to deliver actionable information on detected variants and immunotherapy biomarkers, such as tumor mutational burden (TMB) and microsatellite instability (MSI). We will also discuss the concordance of the automatic implementation of the AMP/ASCO/CAP guidelines with manual expert classifications.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    OCT 10, 2019 12:00 PM PDT

    Tumor Mutation Burden: Challenges and opportunities of measuring and interpreting tumor mutational burden for patient care

    Sponsored by: QIAGEN
    C.E. Credits: P.A.C.E. CE Florida CE

    Specialty

    Cancer

    Immunology

    Molecular Biology

    Cancer Research

    Cancer Diagnostics

    Clinical Diagnostics

    Dna

    Molecular Diagnostics

    Biomarkers

    Diagnostics

    Tumor

    Antibodies

    Laboratory Testing

    Cancer Therapeutics

    Gene Expression

    Geography

    Asia60%

    North America20%

    Europe13%

    Africa7%

    Registration Source

    Website Visitors100%

    Job Title

    Student25%

    Clinical Laboratory Scientist25%

    Educator/Faculty17%

    Research Scientist17%

    Facility/Department Manager8%

    Biologist8%

    Organization

    Academic Institution53%

    Life Science Company13%

    Diagnostic Company7%

    Consultant7%

    Clinical Laboratory7%

    Independent Laboratories7%

    Government7%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more